Table 2. DNA binding domain TP53 missense mutations grouped by tertiary structure.
| High grade serous ovarian cancers | ||||||||
|---|---|---|---|---|---|---|---|---|
| All cases | Optimally cytoreduced cases | |||||||
| Structural groups | N | OS | N | PFS | N | OS | N | PFS |
| Hydrophobic core | 20 | 47.7 | 18 | 14.6 | 15 | 42.9 | 13 | 14.0 |
| Distal loop | 17 | 48.3 | 16 | 14.5 | 12 | 34.4 | 11 | 15.4 |
| L2/L3 | 10 | 39.1 | 10 | 14.7 | 8 | 39.1 | 8 | 17.8 |
| L3 | 13 | 43.3 | 10 | 19.4 | 4 | 45.1 | 4 | 38.0 |
| Major groove | 29 | 57.3 | 27 | 19.1 | 20 | 84.1 | 20 | 19.1 |
| Minor groove | 16 | 36.1 | 16 | 14.1 | 13 | 33.6 | 12 | 17.6 |
| Other MMs | 58 | 44.5 | 43 | 16.1 | 42 | 44.1 | 32 | 15.4 |
| SLH stabilizer | 9 | 31.1 | 9 | 11.2 | 9 | 31.1 | 9 | 11.2 |
| Wild-type | 16 | 30.9 | 14 | 10.1 | 14 | 34.2 | 14 | 10.1 |
| Zinc binder | 13 | 87.0 | 10 | 34.4 | 8 | 87.0 | 7 | 20.7 |
| p-value | 0.048 (0.036a) | 0.038 (0.032a) | 0.020 | 0.180 | ||||
| Reduced groups | N | OS | N | PFS | N | OS | N | PFS |
| Major groove | 29 | 57.3 | 27 | 19.1 | 20 | 84.1 | 20 | 19.1 |
| Minor groove | 16 | 36.1 | 16 | 14.1 | 13 | 33.6 | 12 | 17.6 |
| Other MMs | 118 | 47.4 | 97 | 16.1 | 81 | 44.5 | 68 | 16.1 |
| SLH stabilizer | 9 | 31.1 | 9 | 11.2 | 9 | 31.1 | 9 | 11.2 |
| Wild-type | 16 | 30.9 | 14 | 10.1 | 14 | 34.2 | 14 | 10.1 |
| Zinc binder | 13 | 87.0 | 10 | 34.4 | 8 | 87.0 | 7 | 20.7 |
| p-value | 0.007 | 0.038 | 0.006 | 0.061 | ||||
| All follow-up data truncated at 60 months | ||||||||
| Reduced groups | N | OS | N | PFS | N | OS | N | PFS |
| Major groove | 29 | 57.3 | 27 | 19.1 | 20 | > 60 | 20 | 19.1 |
| Minor groove | 16 | 36.1 | 16 | 14.1 | 13 | 33.6 | 12 | 17.6 |
| Other MMs | 118 | 47.4 | 97 | 16.1 | 81 | 44.5 | 68 | 16.1 |
| SLH stabilizer | 9 | 31.1 | 9 | 11.2 | 9 | 31.1 | 9 | 11.2 |
| Wild-type | 16 | 30.9 | 14 | 10.1 | 14 | 34.2 | 14 | 10.1 |
| Zinc binder | 13 | > 60 | 10 | 34.4 | 8 | > 60 | 7 | 20.7 |
| p-value | 0.007 | 0.038 | 0.006 | 0.061 | ||||
| Risk groups | N | OS | N | PFS | N | OS | N | PFS |
| Lower risk | 42 | > 60 | 37 | 19.8 | 28 | > 60 | 27 | 19.9 |
| Typical risk | 118 | 47.4 | 97 | 16.1 | 81 | 44.5 | 68 | 16.1 |
| Higher risk | 25 | 33.6 | 25 | 11.2 | 22 | 33.6 | 22 | 11.2 |
| Wild-type | 16 | 30.9 | 14 | 10.1 | 14 | 34.2 | 14 | 10.1 |
| p-value | 0.001 | 0.014 | 0.002 | 0.023 | ||||
| Breast cancers | ||||
|---|---|---|---|---|
| All follow-up data truncated at 60 months | ||||
| Reduced groups | N | OS | N | PFS |
| Major groove | 15 | > 60 | 14 | > 60 |
| Minor groove | 5 | 21.4 | 5 | 19.0 |
| Other MMs | 104 | > 60 | 94 | > 60 |
| SLH stabilizer | 7 | 51.4 | 3 | > 60 |
| Zinc binder | 13 | > 60 | 12 | > 60 |
| p-value | 0.153 | 0.435 | ||
| Risk groups | N | OS | N | PFS |
| Lower risk | 28 | > 60 | 26 | > 60 |
| Typical risk | 104 | > 60 | 94 | > 60 |
| Higher risk | 12 | 51.4 | 8 | > 60 |
| p-value | 0.085 (0.033b) | 0.917 | ||
OS: median overall survival (months), PFS: median progression free survival (months), L2/L3:Loop 2/Loop3 interaction stabilizers, L3: Loop 3 stabilizers, MM: missense mutation, SLH: sheet-loop-helix.
a
Log-rank (10 groups) with Kaplan-Meier analysis stratified by cytoreduction status.
b
From difference of likelihood ratios between Cox proportional-hazards regression models with or without Risk groups.